A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer
Phase 2 Terminated
50 enrolled 18 charts
AcceleRET-Lung
Phase 3 Terminated
223 enrolled 18 charts
ELEVATE HNSCC
Phase 2 Terminated
193 enrolled 27 charts
CARMEN-LC05
Phase 2 Terminated
57 enrolled 26 charts
A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)
Phase 3 Terminated
730 enrolled 40 charts
Phase 1b Safety Study of Xevinapant, Weekly Cisplatin, and RT in Participants With Unresected LA SCCHN (HyperlynX)
Phase 1 Terminated
18 enrolled 9 charts
PRESERVE3
Phase 2 Terminated
92 enrolled 24 charts
FIGHT-302
Phase 3 Terminated
167 enrolled
A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors
Phase 1 Terminated
94 enrolled 28 charts
A Phase I Clinical Study for Evaluating the Safety and Efficacy of MASCT-I in Patients With Advanced Solid Tumors
Phase 1 Terminated
105 enrolled
A Phase II Trial of PG2 in Patients With Advanced Pharyngeal or Laryngeal Squamous Cell Carcinoma Under Concurrent Chemoradiotherapy
Phase 2 Terminated
17 enrolled
A Study of BMS-986315 and Nivolumab in Combination With Chemotherapy in Participants With First-line Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)
Phase 2 Terminated
1 enrolled 4 charts
CONTERNO
Phase 3 Terminated
25 enrolled 10 charts
DIGEST
Phase 3 Terminated
361 enrolled 18 charts
Study to Assess the Effects of GS-3583 in Participants With Advanced Solid Tumors
Phase 1 Terminated
13 enrolled 18 charts
SCLC
Phase 1/2 Terminated
213 enrolled 16 charts
QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.
Phase 1/2 Terminated
9 enrolled 18 charts
Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations
Phase 3 Terminated
48 enrolled 26 charts
Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer
Phase 3 Terminated
8 enrolled 7 charts
EPIC
Phase 2 Terminated
4 enrolled 6 charts
REPLATINUM
Phase 3 Terminated
18 enrolled
M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)
Phase 2 Terminated
153 enrolled 13 charts
Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L BTC
Phase 2/3 Terminated
309 enrolled 17 charts
A Dose Escalation Study of Adavosertib(MK1775) in Combination With 5-FU or 5-FU/CDDP in Patients With Advanced Solid Tumor (1775-005
Phase 1 Terminated
11 enrolled 10 charts
MK-1775-008
Phase 1/2 Terminated
7 enrolled 6 charts
Safety And Efficacy Study Of Avelumab Plus Chemotherapy With Or Without Other Anti-Cancer Immunotherapy Agents In Patients With Advanced Malignancies
Phase 1/2 Terminated
67 enrolled 24 charts
TELE-ABC
Phase 2 Terminated
53 enrolled 47 charts
PROPEL
Phase 1/2 Terminated
162 enrolled 21 charts
NTX-301 Monotherapy in Advanced Solid Tumours and in Combination With Platinum-based Chemotherapy in Advanced Ovarian & Bladder Cancer and in Combination With Temozolomide in High-grade Glioma
Phase 1/2 Terminated
12 enrolled
IBI188 Combination Therapy in Solid Tumors
Phase 1 Terminated
9 enrolled
PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients
Phase 1 Terminated
111 enrolled
A Study of L-DOS47 in Combination With Vinorelbine/Cisplatin in Lung Adenocarcinoma
Phase 2 Terminated
9 enrolled
Efficacy and Safety of OncoGelâ„¢ Added to Chemotherapy and Radiation Before Surgery in Subjects With Esophageal Cancer
Phase 2 Terminated
137 enrolled 9 charts
Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer
Phase 1/2 Terminated
92 enrolled 15 charts
Evaluation of Symptom Benefit Rate of Trabectedin/PLD in Patients With Recurrent Ovarian Cancer
Phase 3 Terminated
9 enrolled
A Study of PEP503 With Radiotherapy in Combination With Concurrent Chemotherapy for Patients With Head and Neck Cancer
Phase 1/2 Terminated
12 enrolled
Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Anti-Cancer Agents in Japanese Participants With Gastric or Gastroesophageal Junction Adenocarcinoma
Phase 1 Terminated
36 enrolled 17 charts
A Study of Aflibercept Administered in Combination With Pemetrexed and Cisplatin in Participants With Advanced Carcinoma
Phase 1/2 Terminated
60 enrolled 24 charts
Phase Ib/II Study of M3814 With Etoposide and Cisplatin in Small Cell Lung Cancer (SCLC) Extensive Disease (ED)
Phase 1 Terminated
2 enrolled
PINNACLE
Phase 1/2 Terminated
172 enrolled 17 charts
ARTEMIS
Phase 2 Terminated
124 enrolled 10 charts
A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients With Extensive Stage Small Cell Lung Cancer
Phase 1 Terminated
28 enrolled
A Phase I/II Study to Determine the Maximum Tolerated Dose (MTD) and Safety of CC-4047 (Pomalidomide) Administered in Conjunction With Cisplatin and Etoposide
Phase 1/2 Terminated
22 enrolled 13 charts
Efficacy and Safety Study of PDT Using Photofrin in Unresectable Advanced Perihilar Cholangiocarcinoma (OPUS)
Phase 3 Terminated
28 enrolled 24 charts
Nivolumab and Epacadostat With Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Non-Small Cell Lung Cancer
Phase 3 Terminated
2 enrolled 6 charts
Nintedanib (BIBF 1120) in Mesothelioma
Phase 2/3 Terminated
545 enrolled 15 charts
A Study of Atezolizumab Compared With Gemcitabine Plus (+) Cisplatin or Carboplatin for PD-L1-Selected Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower111)
Phase 3 Terminated
8 enrolled 9 charts
A Safety Study in Participants With Advanced Solid Tumors
Phase 1 Terminated
234 enrolled 23 charts
Patritumab With Cetuximab and a Platinum Agent for Squamous Cell Carcinoma (Cancer) of the Head and Neck (SCCHN )
Phase 2 Terminated
87 enrolled 13 charts
Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004)
Phase 1/2 Terminated
15 enrolled 11 charts